MYGN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Myriad Genetics Inc · Healthcare · Diagnostics & Research

Open interactive chart View report data
Latest close 2.86 USD
-49.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -41.4% below the Trend Line and sits at 0.9% of its 52-week range. The latest completed week returned -49.0%, after a -52.3% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 63/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: earnings are due in 2d.

Setup score 29 out of 100
Latest Close 2.86 USD 31 Jul 2026
1W Return -49.0% latest completed week
4W Return -52.3% short-term follow-through
12W Return -33.3% quarterly tape
Trend Breadth 23.1% 12 of 52 weeks active
Volume Ratio 2.4x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 44.38% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -49.0% Latest completed week; four-week move -52.3%. Indicator stack 13/65 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 44.38% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 63/100 conviction; expected move 11.4%. News sentiment 47/100 45 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -41.4% below the Trend Line and sits at 0.9% of its 52-week range. The latest completed week returned -49.0%, after a -52.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.4x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3212-week average 0.12

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.32Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -52.3% over four weeks, -33.3% over 12 weeks, and -26.9% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-49.0%
4W-52.3%
12W-33.3%
26W-49.1%
52W-26.9%
Active trend streak0 weeks
Active weeks in one year12
Trend breadth23.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.87Latest activity-pressure read.
Pressure change-13.6%Four-week change in activity pressure.
Leadership-55.26Latest relative-leadership reading.
RS change-444.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength24/100Blend of value, momentum, and quality. Underlying universe rank 77; rank 1 is best.
Value31/100Relative valuation strength. Underlying universe rank 70; rank 1 is best.
Quality15/100Profitability and accounting quality. Underlying universe rank 86; rank 1 is best.
Momentum75/100Medium-term price momentum. Underlying universe rank 26; rank 1 is best.
Growth25/100Revenue and earnings growth. Underlying universe rank 76; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.6x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
70.0%
Gross profit retained from each unit of revenue.
Operating margin
-46.6%
Operating profit retained from revenue.
Free-cash-flow margin
2.8%
Free cash flow generated from revenue.
Return on invested capital
-68.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-0.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
17.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

MYGN shows volatility options pressure with a 63/100 conviction score, put-call volume ratio of 0.08, expected move of 11.4%, and Sharemaestro trend signal inactive.

Conviction63/100
Expected move11.4%
Put/call volume0.08
Pressure95
Speculation60
Volatility96
Trend agreement0
Open options detail
Insider activity12 / 4

12 acquisitions and 4 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment47/100

Weighted news tone is neutral across 45 relevant articles.

12 positive · 21 neutral · 12 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move11.4%Nearest-chain priced movement where available.
52-week drawdown-66.7%Distance below the 52-week high.
13-week volatility17.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+29.5%Week of 26 Jun.
Worst week-49.0%Week of 31 Jul.
Latest week-49.0%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains3
Flat weeks0
Modest losses2
Sharp losses12
Recent vol17.7%13-week weekly-return volatility.
Base vol14.1%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew9.6% / -8.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape31/100

Trend, activity pressure, participation, and risk combine to a 31/100 tape read.

 Indicator analysis35/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.32; No reversal markers Next-Week ExpectancyNegative 44.38%

Next-week expectancy is negative with a 44.38% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors33/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 58; Small Cap Core rank 71 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options38/100

MYGN shows volatility options pressure with a 63/100 conviction score, put-call volume ratio of 0.08, expected move of 11.4%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 11.4% Sentiment47/100

Weighted news tone is neutral across 45 relevant articles.

Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.75, Implies 7% Upside Insiders12 / 4

12 acquisitions and 4 disposals in the latest 180-day insider tape.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.86 USD-49.0%4.88 USD13.28 USD0.87-55.2621.1MOff
24 Jul 20265.61 USD-9.2%4.99 USD13.39 USD1.26-12.293.5MOff
17 Jul 20266.18 USD6.0%5.02 USD13.50 USD1.48-4.864.5MOff
10 Jul 20265.83 USD-2.7%5.03 USD13.60 USD1.29-13.825.4MOff
3 Jul 20265.99 USD1.9%5.08 USD13.71 USD1.01-10.156.5MOff
26 Jun 20265.88 USD29.5%5.11 USD13.82 USD0.79-11.3511.7MOff
19 Jun 20264.54 USD4.8%5.17 USD13.93 USD0.39-34.815.7MOff
12 Jun 20264.33 USD-5.3%5.27 USD14.05 USD0.23-36.586.5MOff
5 Jun 20264.57 USD15.1%5.34 USD14.17 USD0.11-32.019.2MOff
29 May 20263.97 USD3.9%5.40 USD14.29 USD0.05-43.969.8MOff
22 May 20263.82 USD6.7%5.54 USD14.41 USD0.10-44.828.7MOff
15 May 20263.58 USD-16.6%5.68 USD14.53 USD0.12-47.907.7MOff
8 May 20264.29 USD-10.6%5.82 USD14.63 USD0.20-38.1314.6MOff
1 May 20264.80 USD0.4%5.93 USD14.72 USD-0.09-27.256.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.